ArticleEndocrine2023
Triglyceride-glucose index is associated with the risk of chronic kidney disease progression in type 2 diabetes.
Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Association between triglyceride-glucose index and clinical outcomes among patients with chronic kidney disease: a meta-analysis.BMC nephrology · 2025Pooled it
- Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis.Cardiovascular diabetology · 2024Pooled it
- Triglyceride-glucose index, neutrophil-to-lymphocyte ratio, and high-sensitivity C-reactive protein across albuminuria stages in type 2 diabetes.Scientific reports · 2026Article
- Triglyceride-Glucose Index and Risk of End-Stage Kidney Disease in Young Adults: National Population-Based Cohort Study.JMIR public health and surveillance · 2026Article
- Prognostic value of the triglyceride-glucose (TyG) index for renal function progression in patients with CKD stages 3-4.Frontiers in nutrition · 2026Article
- Association of triglyceride-glucose index with diabetic kidney disease in patients with type 2 diabetes.Journal of diabetes and metabolic disorders · 2025Article
- The role of insulin resistance in the longitudinal progression from NAFLD to cardiovascular-kidney-metabolic disease.Cardiovascular diabetology · 2025Article
- Evaluating the impact of chronic kidney disease and the triglyceride-glucose index on cardiovascular disease: mediation analysis in the NHANES.BMC public health · 2024Article
- Triglyceride-glucose index change and chronic kidney disease progression in a Chinese hypertensive population.Frontiers in endocrinology · 2024Article
- Role of Triglyceride-Glucose Index in Type 2 Diabetes Mellitus and Its Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Triglyceride glucose index and renal function decline in Han Chinese hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2023Article
- Counterintuitive relationship between the triglyceride glucose index and diabetic foot in diabetes patients: A cross-sectional study.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe study aimed to investigate the association of TyG index with chronic kidney disease (CKD) progression in type 2 diabetes mellitus (T2DM).
methodsA total of 179 T2DM patients with CKD were retrospectively included. CKD progression was defined as a doubling of baseline serum creatinine or onset of end-stage kidney disease (ESKD). Internal validation was performed by the Kidney Failure Risk Equation (KFRE) model and Net reclassification improvement (NRI).
resultsThe optimal cut-off value of the TyG index was 9.17. The cumulative incidence of kidney outcomes was significantly higher in the high-TyG group (v.s low-TyG group, P = 0.019). In addition, the high-TyG index was associated with a greater risk of CKD progression (HR 1.794, 95% CI 1.026-3.137, P = 0.040). And reclassification analyses confirmed the final adjusted model improved NRI (61.90% v.s model 2, 43.80% v.s model 1). The further RCS curves presented an inverted S-shaped relationship between the TyG index and the risk of CKD progression. Internal validation verified that a higher TyG index was associated with 2.10-fold increased odds of 2-year ESKD risk >10% (95% CI 1.82-8.21). Moreover, subgroup analysis suggested that the association was more pronounced in those at relatively early CKD stages (higher than stage 2) and with no medication history of oral hypoglycemic agents.
conclusionAn elevated TyG index was associated with a higher risk of CKD progression in T2DM patients. Our findings suggested that timely targeting insulin sensitivity at the early stages of T2DM might be associated with declined future risk of CKD development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.